-
5-Star Biotech Stock Watch: Aegerion Pharmaceuticals
Wednesday, July 9, 2014 - 3:30pm | 382Read More...The Nasdaq Composite got hammered Tuesday. The Russell was also slammed pretty hard. The Russell, in particular, broke a key trendline of support, which implies more selling to come. And if you’ve been in the market this year then Tuesday's price action reminds you of March and April...
-
Walgreen Co. Or CVS Caremark: Which Would You Rather?
Tuesday, July 8, 2014 - 3:35pm | 624Read More...The business of chain drugstores has been a veritable model for how just about any retail business should envision itself. Over the past 75 years, chain drugstores have seen staggeringly consistent growth while becoming an increasingly pervasive part of America's cultural landscape. With...
-
Advances In HIV, Hep C Treatments Could Spark Renewed Interest In Biotech Stocks
Wednesday, June 18, 2014 - 9:38am | 768Read More...This month marks 33 years since the U.S. Centers for Disease Control and Prevention (CDC) reported on a rare lung infection affecting a group of gay men – one of the first known medical mentions of what later became known as the AIDS outbreak. The World Health Organization says that, over...
-
Biogen Raises Full-Year Earnings, But Is That The Entire Picture?
Thursday, April 24, 2014 - 5:03pm | 686Read More...One of the best performers in the incredible bull run for the market has been the biotech sector. Many of the stocks in the sector have doubled, tripled, quadrupled and, in the case of Biogen (NASDAQ: BIIB), decupled (ten times) in price. BIIB, which bottomed in Nov. 2008 ($37.21) and peaked...
-
Biotech ETFs Come Back Down To Earth
Thursday, March 27, 2014 - 4:29pm | 483Read More...Biotech stocks have been one of the hottest sectors of the market over the last several years and many exchange traded funds have benefitted greatly from their success. The two largest ETFs in this space are the iShares NASDAQ Biotechnology ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSE:...
-
Procter & Gamble vs. Johnson & Johnson: Which is the Better Bet?
Wednesday, January 8, 2014 - 4:42pm | 547Read More...When looking to make an investment, some investors might look to get into what’s “in” or what’s “hot.” This is why gold has recently been on an amazing bull run (which is now effectively over), and why housing was hot before it. Much of this can be seen as a...
-
GlaxoSmithKline Rocked By China Bribery Scandal
Thursday, December 19, 2013 - 4:48pm | 285Read More...A bribery scandal in China is forcing GlaxoSmithKline (NYSE: GSK) to review all of its business practices, The Financial Times reported. Four of GlaxoSmithKline's top Chinese executives have been arrested and dozens more questioned in an ongoing corruption investigation. Chinese police allege...
-
Food Allergy Bill Offers Financial Incentives for States That Have Emergency Meds at Schools
Wednesday, November 13, 2013 - 3:22pm | 637Read More...If you have a school-age child, you probably know how serious the issue of food allergies -- and an allergic reaction -- can be. The Centers for Disease Control and Prevention says about 88 percent of the nation's schools have one or more students with a serious food allergy – a health...
-
Pfizer Partnering With Zacharon To Develop Rare-Disease Drugs
Wednesday, April 6, 2011 - 1:52pm | 112Read More...Pfizer (NYSE: PFE) is expected to formally announce Thursday a $210 million partnership with Zacharon Pharmaceuticals. The collaboration is centered around Zacharon's work in developing treatments for genetic diseases known as “lysosomal storage disorders”. This partnership marks the first such...









